ABN Amro Investment Solutions Cuts Stake in Elevance Health, Inc. $ELV

ABN Amro Investment Solutions cut its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 80.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,270 shares of the company’s stock after selling 9,128 shares during the period. ABN Amro Investment Solutions’ holdings in Elevance Health were worth $733,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in Elevance Health by 3.2% in the second quarter. Vanguard Group Inc. now owns 22,856,898 shares of the company’s stock valued at $8,890,419,000 after buying an additional 704,790 shares during the last quarter. Sanders Capital LLC increased its holdings in shares of Elevance Health by 24.7% during the second quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock valued at $2,265,773,000 after acquiring an additional 1,152,440 shares in the last quarter. Artisan Partners Limited Partnership increased its holdings in shares of Elevance Health by 9.7% during the second quarter. Artisan Partners Limited Partnership now owns 3,675,179 shares of the company’s stock valued at $1,429,498,000 after acquiring an additional 324,399 shares in the last quarter. Norges Bank purchased a new position in shares of Elevance Health in the 2nd quarter valued at approximately $1,148,379,000. Finally, Massachusetts Financial Services Co. MA grew its position in Elevance Health by 4.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,440,630 shares of the company’s stock worth $788,616,000 after purchasing an additional 112,020 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Analysts Set New Price Targets

ELV has been the subject of a number of research analyst reports. Truist Financial decreased their price target on shares of Elevance Health from $400.00 to $390.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $332.00 target price on shares of Elevance Health in a research note on Thursday, January 29th. Leerink Partners boosted their price target on Elevance Health from $350.00 to $357.00 and gave the company a “market perform” rating in a research note on Thursday, January 29th. Royal Bank Of Canada cut Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price objective for the company. in a research note on Tuesday, February 3rd. Finally, Zacks Research raised Elevance Health from a “strong sell” rating to a “hold” rating in a report on Thursday, November 6th. Twelve analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Elevance Health currently has a consensus rating of “Moderate Buy” and an average target price of $390.55.

Elevance Health Stock Up 3.1%

Elevance Health stock opened at $346.49 on Tuesday. The business’s 50-day moving average price is $352.53 and its 200 day moving average price is $332.74. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. The firm has a market cap of $76.47 billion, a price-to-earnings ratio of 13.79, a price-to-earnings-growth ratio of 1.93 and a beta of 0.50. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $458.75.

Elevance Health (NYSE:ELV) last released its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping the consensus estimate of $3.10 by $0.23. The business had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, sell-side analysts anticipate that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be given a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date is Tuesday, March 10th. Elevance Health’s payout ratio is currently 27.23%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.